Related Experiment Video
Updated: Jan 19, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
An HIV-infected Patient with No Serious Adverse Events after Overdosing on Raltegravir
Tomohiro Hosoda1, Yuki Uehara1, Toshio Naito1
1Department of General Medicine, Juntendo University School of Medicine, Japan.
Abstract:
Patients with HIV infection represent a high-risk group for medication overdose because of the high frequency of complicating psychiatric disorders. Raltegravir is well-known for its low frequency of adverse effects. We herein report a 42-year-old Japanese man with HIV infection who was hospitalized 6 hours after overdosing with 24,000 mg of raltegravir in a suicide attempt. No serious adverse events occurred, although the plasma concentration of raltegravir at 18 hours after the overdose was 79,871.1 ng/mL. Raltegravir may be well-indicated for HIV patients at risk of overdosing.
Related Concept Videos
Retrovirus Life Cycles
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Pharmacokinetics in Pediatric Patients: Drug Excretion
Retroviruses
Bioavailability Study Design: Healthy Subjects Versus Patients

